1.Infante-Garcia C. and Garcia-Alloza M. Review of the Effect of Natural Compounds and Extracts on Neurodegeneration in Animal Models of Diabetes Mellitus. International journal of molecular sciences 20(10), 2019.
2.Dalli T., Beker M., Terzioglu-Usak S., Akbas F. and Elibol B. Thymoquinone activates MAPK pathway in hippocampus of streptozotocin-treated rat model. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 99:391–401, 2018.
3.Albai O., Frandes M., Timar R., Roman D. and Timar B. Risk factors for developing dementia in type 2 diabetes mellitus patients with mild cognitive impairment. Neuropsychiatric disease and treatment 15:167–175, 2019.
4.Xu P., Zhang Y., Jiang X., Li J., Song L., Khoso M. H., Liu Y., Wu Q., Ren G. and Li D. Canine Fibroblast Growth Factor 21 Ameliorates Hyperglycemia Associated with Inhibiting Hepatic Gluconeogenesis and Improving Pancreatic Beta-Cell Survival in Diabetic Mice and Dogs. PloS one 11(5):e0155598, 2016.
5.Aghanoori M. R., Smith D. R., Roy Chowdhury S., Sabbir M. G., Calcutt N. A. and Fernyhough P. Insulin prevents aberrant mitochondrial phenotype in sensory neurons of type 1 diabetic rats. Experimental neurology 297:148–157, 2017.
6.DiMeglio M., Furey W., Hajj J., Lindekens J., Patel S., Acker M., Bavaria J., Szeto W. Y., Atluri P., Haber M., Diaz-Arrastia R. and Laudanski K. Observational study of long-term persistent elevation of neurodegeneration markers after cardiac surgery. Scientific reports 9(1):7177, 2019.
7.Rehni A. K., Liu A., Perez-Pinzon M. A. and Dave K. R. Diabetic aggravation of stroke and animal models. Experimental neurology 292:63–79, 2017.
8.Das B.C., Dasgupta S. and Ray S. K. Potential therapeutic roles of retinoids for prevention of neuroinflammation and neurodegeneration in Alzheimer’s disease. Neural regeneration research 14(11):1880–1892, 2019.
9.Dogan H. O. and Alcigir M. E. The Protective effect of P7C3 against DNA and neuron damage in rat pups with congenital hypothyroidism. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 99:499–503, 2018.
10.Wang Q., Yuan J., Yu Z., Lin L., Jiang Y., Cao Z., Zhuang P., Whalen M. J., Song B., Wang X. J., Li X., Lo E. H., Xu Y. and Wang X. FGF21 Attenuates High-Fat Diet-Induced Cognitive Impairment via Metabolic Regulation and Anti-inflammation of Obese Mice. Molecular neurobiology 55(6):4702–4717, 2018.
11.Xu P., Zhang Y., Liu Y., Yuan Q., Song L., Liu M., Liu Z., Yang Y., Li J., Li D. and Ren G. Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-beta/smad2/3 and NF-kappaB signaling pathways. Toxicology and applied pharmacology 290:43–53, 2016.
12.Geng J., Wang L., Zhang L., Qin C., Song Y., Ma Y., Chen Y., Chen S., Wang Y., Zhang Z. and Yang G. Y. Blood-Brain Barrier Disruption Induced Cognitive Impairment Is Associated With Increase of Inflammatory Cytokine. Frontiers in aging neuroscience 10:129, 2018.
13.Mamo J. C. L., Lam V., Brook E., Mooranian A., Al-Salami H., Fimognari N., Nesbit M. and Takechi R. Probucol prevents blood–brain barrier dysfunction and cognitive decline in mice maintained on pro-diabetic diet. Diabetes and Vascular Disease Research 16(1):87–97, 2018.
14.Bogush M., Heldt N. A. and Persidsky Y. Blood Brain Barrier Injury in Diabetes: Unrecognized Effects on Brain and Cognition. Journal of neuroimmune pharmacology: the official journal of the Society on NeuroImmune Pharmacology 12(4):593–601, 2017.
15.Campos-Pires R., Hirnet T., Valeo F., Ong B. E., Radyushkin K., Aldhoun J., Saville J., Edge C. J., Franks N. P., Thal S. C. and Dickinson R. Xenon improves long-term cognitive function, reduces neuronal loss and chronic neuroinflammation, and improves survival after traumatic brain injury in mice. British journal of anaesthesia 123(1):60–73, 2019.
16.Buoncervello M., Maccari S., Ascione B., Gambardella L., Marconi M., Spada M., Macchia D., Stati T., Patrizio M., Malorni W., Matarrese P., Marano G. and Gabriele L. Inflammatory cytokines associated with cancer growth induce mitochondria and cytoskeleton alterations in cardiomyocytes. Journal of cellular physiology 234(11):20453–20468, 2019.
17.Gupta M. and Kaur G. Withania somnifera (L.) Dunal ameliorates neurodegeneration and cognitive impairments associated with systemic inflammation. BMC complementary and alternative medicine 19(1):217, 2019.
18.Badshah H., Ali T. and Kim M. O. Osmotin attenuates LPS-induced neuroinflammation and memory impairments via the TLR4/NFkappaB signaling pathway. Scientific reports 6:24493, 2016.
19.Chau M. D., Gao J., Yang Q., Wu Z. and Gromada J. Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC–1alpha pathway. Proceedings of the National Academy of Sciences of the United States of America 107(28):12553–12558, 2010.
20.Kilic U., Elibol B., Uysal O., Kilic E., Yulug B., Sayin Sakul A. and Babacan Yildiz G. Specific alterations in the circulating levels of the SIRT1, TLR4, and IL7 proteins in patients with dementia. Experimental gerontology 111:203–209, 2018.
21.Li H. and Wang R. Blocking SIRT1 inhibits cell proliferation and promotes aging through the PI3K/AKT pathway. Life sciences 190:84–90, 2017.
22.Xu P., Ye X., Zhang Y., Yuan Q., Liu M., Wu Q., Ren G. and Li D. Long-acting hypoglycemic effects of PEGylated FGF21 and insulin glargine in mice with type 1 diabetes. Journal of diabetes and its complications 29(1):5–12, 2015.
23.Mogi M. and Horiuchi M. Neurovascular coupling in cognitive impairment associated with diabetes mellitus. Circulation journal: official journal of the Japanese Circulation Society 75(5):1042–1048, 2011.
24.Bookout A. L., de Groot M. H., Owen B. M., Lee S., Gautron L., Lawrence H. L., Ding X., Elmquist J. K., Takahashi J. S., Mangelsdorf D. J. and Kliewer S. A. FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nature medicine 19(9):1147–1152, 2013.
25.Xu P., Zhang Y., Song L., Khoso M. H., Li J., Jiang X., He J., Li J., Ma X., Ren G. and Li D. Efficacy of a combination of high and low dosage of PEGylated FGF–21 in treatment of diabetes in db/db mice. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 84:97–105, 2016.
26.Owen B. M., Ding X., Morgan D. A., Coate K. C., Bookout A. L., Rahmouni K., Kliewer S. A. and Mangelsdorf D. J. FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell metabolism 20(4):670–677, 2014.
27.Li H., Wu G., Fang Q., Zhang M., Hui X., Sheng B., Wu L., Bao Y., Li P., Xu A. and Jia W. Fibroblast growth factor 21 increases insulin sensitivity through specific expansion of subcutaneous fat. Nature communications 9(1):272, 2018.
28.Sunaga H., Koitabashi N., Iso T., Matsui H., Obokata M., Kawakami R., Murakami M., Yokoyama T. and Kurabayashi M. Activation of cardiac AMPK-FGF21 feed-forward loop in acute myocardial infarction: Role of adrenergic overdrive and lipolysis byproducts. Scientific reports 9(1):11841, 2019.
29.Byun K., Yoo Y., Son M., Lee J., Jeong G. B., Park Y. M., Salekdeh G. H. and Lee B. Advanced glycation end-products produced systemically and by macrophages: A common contributor to inflammation and degenerative diseases. Pharmacology & therapeutics 177:44–55, 2017.
30.Kruyer A., Soplop N., Strickland S. and Norris E. H. Chronic Hypertension Leads to Neurodegeneration in the TgSwDI Mouse Model of Alzheimer’s Disease. Hypertension 66(1):175–182, 2015.
31.Wang C., Yang S., Zhang N., Mu Y., Ren H., Wang Y. and Li K. Long-term supranutritional supplementation with selenate decreases hyperglycemia and promotes fatty liver degeneration by inducing hyperinsulinemia in diabetic db/db mice. PloS one 9(7):e101315, 2014.
32.Chen S., Chen S. T., Sun Y., Xu Z., Wang Y., Yao S. Y., Yao W. B. and Gao X. D. Fibroblast growth factor 21 ameliorates neurodegeneration in rat and cellular models of Alzheimer’s disease. Redox biology 22:101133, 2019.
33.Berglund E. D., Li C. Y., Bina H. A., Lynes S. E., Michael M. D., Shanafelt A. B., Kharitonenkov A. and Wasserman D. H. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 150(9):4084–4093, 2009.
34.Feng C. W., Chen N. F., Sung C. S., Kuo H. M., Yang S. N., Chen C. L., Hung H. C., Chen B. H., Wen Z. H. and Chen W. F. Therapeutic Effect of Modulating TREM–1 via Anti-inflammation and Autophagy in Parkinson’s Disease. Frontiers in neuroscience 13:769, 2019.
35.Yoo D. Y., Yim H. S., Jung H. Y., Nam S. M., Kim J. W., Choi J. H., Seong J. K., Yoon Y. S., Kim D. W. and Hwang I. K. Chronic type 2 diabetes reduces the integrity of the blood-brain barrier by reducing tight junction proteins in the hippocampus. The Journal of veterinary medical science 78(6):957–962, 2016.
36.Yin J., Wang H. and Lu G. Umbelliferone alleviates hepatic injury in diabetic db/db mice via inhibiting inflammatory response and activating Nrf2-mediated antioxidant. Bioscience reports 38(4), 2018.
37.Li D. W., Zhou F. Z., Sun X. C., Li S. C., Yang J. B., Sun H. H. and Wang A. H. Ginsenoside Rb1 protects dopaminergic neurons from inflammatory injury induced by intranigral lipopolysaccharide injection. Neural regeneration research 14(10):1814–1822, 2019.
38.Liu M., Yin L., Li W., Hu J., Wang H., Ye B., Tang Y. and Huang C. C1q/TNF‐related protein‐9 promotes macrophage polarization and improves cardiac dysfunction after myocardial infarction. Journal of cellular physiology, 2019.
39.Liu P., Peng J., Han G. H., Ding X., Wei S., Gao G., Huang K., Chang F. and Wang Y. Role of macrophages in peripheral nerve injury and repair. Neural regeneration research 14(8):1335–1342, 2019.
40.Kanungo J., Zheng Y. L., Amin N. D. and Pant H. C. Targeting Cdk5 activity in neuronal degeneration and regeneration. Cellular and molecular neurobiology 29(8):1073–1080, 2009.
41.Jin W., Xu X., Chen X., Qi W., Lu J., Yan X., Zhao D., Cong D., Li X. and Sun L. Protective effect of pig brain polypeptides against corticosterone-induced oxidative stress, inflammatory response, and apoptosis in PC12 cells. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 115:108890, 2019.
42.Zhu Z., Kremer P., Tadmori I., Ren Y., Sun D., He X. and Young W. Lithium suppresses astrogliogenesis by neural stem and progenitor cells by inhibiting STAT3 pathway independently of glycogen synthase kinase 3 beta. PloS one 6(9):e23341, 2011.
43.Hardie D. G., Ross F. A. and Hawley S. A. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nature Reviews Molecular Cell Biology 13(4):251–262, 2012.
44.Yang H., Feng A., Lin S., Yu L., Lin X., Yan X., Lu X. and Zhang C. Fibroblast growth factor–21 prevents diabetic cardiomyopathy via AMPK-mediated antioxidation and lipid-lowering effects in the heart. Cell death & disease 9(2):227, 2018.
45.Salimian N., Peymani M., Ghaedi K. and Nasr Esfahani M. H. Modulation in miR–200a/SIRT1axis is associated with apoptosis in MPP(+)-induced SH-SY5Y cells. Gene 674:25–30, 2018.
46.Wang S., Wang Y., Zhang Z., Liu Q. and Gu J. Cardioprotective effects of fibroblast growth factor 21 against doxorubicin-induced toxicity via the SIRT1/LKB1/AMPK pathway. Cell death & disease 8(8):e3018, 2017.
47.He Y., Kim B. G., Kim H. E., Sun Q., Shi S., Ma G., Kim Y., Kim O. S. and Kim O. J. The Protective Role of Feruloylserotonin in LPS-Induced HaCaT Cells. Molecules 24(17), 2019.
48.Holen E., Araujo P., Xie S., Softeland L. and Espe M. Resveratrol inhibited LPS induced transcription of immune genes and secretion of eicosanoids in Atlantic salmon (Salmo salar), comparing mono-, co- and a novel triple cell culture model of head kidney leukocytes, liver cells and visceral adipocyte tissue. Comparative biochemistry and physiology. Toxicology & pharmacology: CBP 224:108560, 2019.
49.Xue S., Shao Q., Zhu L. B., Jiang Y. F., Wang C., Xue B., Lu H. M., Sang W. L. and Ma J. Z. LDC000067 suppresses RANKL-induced osteoclastogenesis in vitro and prevents LPS-induced osteolysis in vivo. International immunopharmacology 75:105826, 2019.